Vaccination before surgery to treat advanced ovarian cancer
Part of Cancer, Hormones & metabolism, Women’s health & pregnancy clinical trials.
This trial studies a vaccine made from your immune cells (dendritic cell vaccine) given before chemotherapy and surgery. It aims to help your body recognize and fight ovarian cancer more effectively in people whose cancer is advanced and spread.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman age 18 or older with confirmed epithelial ovarian cancer from biopsy or surgery
- Your cancer is too hard to remove with first surgery, so you need chemotherapy first and then interval debulking surgery
- Your cancer type is serous (high-grade or low-grade), and it is stage IIIb/IIIc/IVa/IVb with specific lymph node spread limits
- Your general health is fairly good (performance status 0–1) and your blood counts and liver/kidney tests are within required ranges
- You can safely take part in the study, including giving consent, having planned follow-up, and being able to do a tumor biopsy
- You are not pregnant (and if you could become pregnant, you must use effective birth control); you also must not have certain infections or immune conditions
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a personalized vaccine for people with epithelial ovarian cancer who still have a small amount of cancer DNA in their blood after surgery. The goal is to see if the vaccine can help stop the cancer from coming back.
This study looks at how the immune system works in people with epithelial ovarian cancer. It aims to understand the immune landscape around the tumor, which could lead to better treatments in the future.
This trial tests a new combination of treatments for advanced ovarian, fallopian tube, or peritoneal cancer. It combines chemotherapy and immunotherapy (drugs that help your immune system fight cancer) with a special vaccine made from your own tumor. The goal is to see if this approach is more effective than standard treatment.
This Phase 2 trial studies a maintenance vaccine (DCVAC/OvCa) given after standard first-line chemotherapy and surgery for certain advanced ovarian cancers. It aims to help keep the cancer from coming back for longer by boosting the body’s anti-cancer response.
This trial tests a vaccine called CryptiVax-1001 for people with advanced ovarian cancer who have finished first-line chemotherapy and are in remission, as maintenance therapy. The goal is to see if the vaccine can help keep the cancer from coming back.
This trial is testing a combination of two new immunotherapy drugs (iparomlimab and tuvonralimab) given before surgery and together with chemotherapy for advanced ovarian cancer. It aims to see if this approach can shrink the cancer more effectively and improve outcomes.
Hear when a new Epithelial Ovarian Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.